 After the discovery of HEPT and TIBO, compounds screening methods were used to develop BI-RG-587, the first NNRTI commonly known as nevirapine.Like HEPT and TIBO, nevirapine blocked viral RT activity by non-competitive inhibition (with respect to dNTP binding).This reinforced the idea that the new class of anti-HIV inhibitors was inhibiting the activity of RT but not at the active site.